Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Gamma Biologicals

This article was originally published in The Gray Sheet

Executive Summary

Gamma Biologicals: Submits 510(k) to FDA for its ReAct gel-based test for the rapid detection of red blood cell antibodies. Consisting of a centrifuge, an incubator and a plastic strip containing an immunoreactive agarose, the ReAct assay's advantages over conventional test tube procedures include ease of use, "stable and reproducible results, fast and short centrifuge time...and clear differentiation between positive and negative results," Gamma says. The company previously has noted that the ReAct technology will cost more per unit than traditional testing methodology but will reduce overall lab costs due to simplified procedures and lower labor costs ("The Gray Sheet" Aug. 21, 1995, p. 11)...
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT006947

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel